Free Trial

AstraZeneca (AZNCF) 10K Form and Latest SEC Filings 2026

AstraZeneca logo
$187.10 0.00 (0.00%)
As of 05/22/2026

Latest AstraZeneca SEC Filings & Recent Activity

AstraZeneca (OTCMKTS:AZNCF) has submitted 993+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in AstraZeneca's financial statements. The most recent filing was a Form 4 submitted on May 22, 2026.

Form 4
ASTRAZENECA PLC Reports Ownership Change on May. 22, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

AstraZeneca SEC Filing History

Browse AstraZeneca's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/22/2026 3:05 PM
AstraZeneca (901832) Issuer
Sharma Mani (2122411) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/18/2026 9:15 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/18/2026 8:42 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/18/2026 8:36 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/14/2026 6:25 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/08/2026 3:05 PM
AstraZeneca (901832) Issuer
Sharma Mani (2122411) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/01/2026 9:23 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/01/2026 7:40 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/01/2026 7:45 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/29/2026 6:23 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/28/2026 10:32 AM
AstraZeneca (901832) Subject
VANGUARD CAPITAL MANAGEMENT LLC (2100119) Filed by
Form SCHEDULE 13G
04/28/2026 6:31 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/27/2026 5:29 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/23/2026 5:10 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/21/2026 5:19 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/20/2026 6:03 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/09/2026 12:01 PM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/08/2026 1:20 PM
AstraZeneca (901832) Subject
NEW YORK STOCK EXCHANGE LLC (876661) Filed by
Form 25-NSE
04/02/2026 8:27 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/01/2026 9:30 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/31/2026 6:48 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/27/2026 7:04 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/20/2026 6:59 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/19/2026 6:51 PM
AstraZeneca (901832) Issuer
Sharma Mani (2122411) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/16/2026 7:45 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/10/2026 7:07 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/10/2026 6:37 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/06/2026 7:11 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/06/2026 6:43 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/06/2026 6:50 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/04/2026 8:14 AM
AstraZeneca (901832) Filer
Form CERT
03/03/2026 3:01 PM
AstraZeneca Finance LLC (1862005) Filer
AstraZeneca (901832) Filer
Form 8-A12B
03/02/2026 11:00 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/26/2026 7:59 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/25/2026 9:40 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/25/2026 7:30 AM
AstraZeneca Finance LLC (1862005) Filer
AstraZeneca (901832) Filer
Form 424B2
Transaction specifc information for a delayed shelf offering
02/24/2026 5:51 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/24/2026 5:45 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/20/2026 5:57 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/10/2026 10:55 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/06/2026 8:48 AM
AstraZeneca (901832) Filed by
Innate Pharma SA (1598599) Subject
Innate Pharma SA (1598599) Subject
Form SCHEDULE 13D/A
Trump's New Dollar (Ad)

Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel

Watch the free briefing and see the three steps to prepare today
02/06/2026 8:54 AM
AstraZeneca (901832) Filed by
Monopar Therapeutics (1645469) Subject
Form SCHEDULE 13G/A
02/03/2026 2:21 PM
AstraZeneca (901832) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
02/03/2026 6:01 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/02/2026 12:26 PM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/02/2026 6:51 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/02/2026 6:25 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/30/2026 5:19 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/29/2026 7:08 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/22/2026 3:28 PM
AstraZeneca (901832) Filer
Form CERT
01/22/2026 3:22 PM
AstraZeneca Finance LLC (1862005) Filer
AstraZeneca (901832) Filer
Form 8-A12B
01/22/2026 3:14 PM
AstraZeneca (901832) Filer
Form CERT
01/20/2026 6:18 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/08/2026 5:04 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/02/2026 11:24 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/22/2025 6:47 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/22/2025 6:18 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/22/2025 6:02 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/19/2025 7:35 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/16/2025 5:42 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/16/2025 5:19 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/04/2025 12:48 PM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/01/2025 10:40 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/01/2025 10:47 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/26/2025 5:27 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/20/2025 7:31 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/17/2025 11:52 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/14/2025 9:12 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/12/2025 4:35 PM
AstraZeneca (901832) Subject
SARIN ARADHANA (1729110) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/10/2025 11:15 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/06/2025 6:36 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/03/2025 12:31 PM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/03/2025 12:22 PM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/03/2025 11:36 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/28/2025 9:10 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/28/2025 7:02 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/22/2025 7:07 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/20/2025 6:12 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/20/2025 5:47 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/14/2025 5:05 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/07/2025 5:30 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/06/2025 6:18 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/01/2025 9:19 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/29/2025 5:59 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/29/2025 6:05 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/29/2025 5:08 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/25/2025 12:27 PM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/22/2025 6:46 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/22/2025 6:39 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/17/2025 6:46 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/17/2025 6:11 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
Musk's shopping list: batteries ✓ solar ✓ data ✓ power ___ (Ad)

Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity for $2.6 billion and Twitter for $44 billion. Now one small company makes the equipment his Colossus supercomputer - a million GPUs consuming nearly $1 billion a month in power - cannot run without. Analyst Dylan Jovine has identified the name and ticker. For investors who own shares before a potential move, the math could be significant.tc pixel

See the stock Musk's acquisition pattern points to next
09/02/2025 5:17 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/28/2025 10:14 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/26/2025 12:22 PM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/21/2025 9:51 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/18/2025 10:07 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/15/2025 9:40 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/12/2025 9:45 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/01/2025 1:32 PM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/29/2025 6:58 AM
AstraZeneca (901832) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
(Data available from 1/1/2016 forward)

AstraZeneca SEC Filings - Frequently Asked Questions

AstraZeneca (AZNCF) has submitted 993+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

The most recent filing was a Form 4 submitted on May 22, 2026. This was an insider ownership change filed by 4 - ASTRAZENECA PLC (0000901832) (Issuer).

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (OTCMKTS:AZNCF) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners